Microbot Medical praises new AMA radiation policy; cites 92% cut with LIBERTY robot

Microbot Medical Inc.

AMA adopted new policy in late 2025 to strengthen protections from ionizing radiation; Microbot commends the move.
LIBERTY system demonstrated 92% relative reduction in radiation exposure in ACCESS-PVI Study.
LIBERTY is FDA-cleared, single-use, remotely operated, designed for precise navigation with reduced radiation.
Limited Market Release began late 2025; Full Market Release planned for April 2026 at SIR conference.
CEO Harel Gadot says LIBERTY can address staffing shortages and improve care for patients and providers.

item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-26-008782
form_type: 8-K
ticker: MBOT
cik: 0000883975
company_name: Microbot Medical Inc.
filed_at: 2026-03-04T23:59:59+00:00
discovered_at: 2026-05-14T18:02:37.911084+00:00
generated_at: 2026-05-15T21:57:06.937752+00:00
sec_items: ["7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.35
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-26-008782
json_url: https://secwatch.observer/filing/0001493152-26-008782.json
markdown_url: https://secwatch.observer/filing/0001493152-26-008782.md
text_url: https://secwatch.observer/filing/0001493152-26-008782.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/883975/000149315226008782/0001493152-26-008782-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/883975/000149315226008782/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-26-008782

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.